ZyGEM announces advancement in microfluidics platform for DNA testing

NewsGuard 100/100 Score

ZyGEM Corp. Ltd., today announced several developments supporting the advancement of its integrated microfluidics platform designed to dramatically decrease the time, complexity and cost of conducting DNA testing. These include presentations at two key scientific meetings, as well as the issuance of a new patent relating to separation technology that supports and further strengthens ZyGEM's intellectual property portfolio.  

"These scientific presentations highlighting how our innovative microfluidics system works and validating its tremendous performance advantages are helping to build interest in our unique approach," said Paul Kinnon, president and CEO of ZyGEM.  "We look forward to sharing additional data with researchers and potential customers as we progress toward beta system placements in the coming months."

At the 21st International Symposium on Human Identification (ISHI), researchers from ZyGEM's MicroLab unit and the company's collaborators presented three sets of studies illustrating how the component elements of the prototype RapI.D.™ system act to speed the DNA analysis process.  RapI.D., which ZyGEM is developing in collaboration with Lockheed Martin, leverages MicroLab's advanced microfluidic research to accelerate the DNA identification process—essentially building a laboratory on a microfluidic chip that dramatically reduces the processing steps, time and effort needed for analysis.  

PCR amplification is the most time consuming of conventional DNA analysis steps, taking two or more hours.  One of the studies presented at ISHI showed how the ZyGEM system conducts PCR amplification up to 10 times more rapidly than conventional approaches, primarily by using infrared-mediated microchip PCR to reduce the time required for thermal cycling and holding.  This study also demonstrated that compared to conventional PCR, infrared-mediated microchip PCR used far less reagent, required less sample and was compatible with commercially available short tandem repeat (STR) amplification kits.

A second study at ISHI demonstrated that rapid microfluidic separations using the ZyGEM approach could be performed on two different detection systems using a plastic microchip, rather than the conventional glass microchip.  The researchers concluded that the much less costly plastic microchips worked as well as their glass counterparts, and could substantially decrease the overall cost of the analysis.

A third ISHI study assessed the overall performance of the prototype integrated microfluidics-based RapI.D. DNA analysis system ZyGEM is developing with Lockheed Martin.  It showed that the multistep process for conventional forensic STR analysis requiring 8-10 hours was completed by the RapI.D. system in less than 60 minutes, extracting DNA from crude samples in as little as four minutes and completing the PCR amplification process in less than 40 minutes, using commercially available reagents.  The data presented supported the capability of the integrated system to produce rapid, automated, "sample in-answer out" genetic analyses for accurate human identification, using standard buccal swab samples.

Dr. James Landers, chief scientific officer of ZyGEM, noted, "It is gratifying to have the opportunity to present data on our revolutionary DNA analysis platform to scientists on the front lines of using DNA to fight crime and improve the criminal justice system.  Their feedback has been invaluable and their enthusiasm for the unprecedented capabilities of our technology reinforces our goal of proceeding to commercialization as soon as feasible."

ZyGEM also announced that CEO Paul Kinnon will participate in the opening keynote session at the 2nd Annual Lab-on-a-Chip World Congress, speaking on the challenges of developing an integrated microfluidic platform for forensic DNA and diagnostic applications and how ZyGEM is addressing them.

Separately, ZyGEM reported that U.S. Patent Number 7,815,802 was issued on October 19, 2010 to the University of Virginia Patent Foundation.  The patent, which is exclusively licensed to ZyGEM, covers important aspects of the fabrication of silica-based phases in microfluidic systems, which uses a process known as photo-polymerization that can be derivatized to efficiently extract DNA from samples.

Dr. Landers added, "This new patent further reinforces the strong intellectual property portfolio we have created to protect the novel microfluidics technology at the heart of our rapid detection system.  It also complements the patents that ZyGEM has obtained for its unique thermophilic enzymes that are of utility both for our integrated microfluidics platform and for other life sciences and industrial applications."

The 2nd Annual Lab-on-a-Chip World Congress, which is designed to review existing and new life science applications of microfluidic technologies, is being held at the Hilton La Jolla Torrey Pines in San Diego, October 28-29, 2010.  For more information, visit www.selectbiosciences.com/conferences/LOACWC2010/index.aspx.

The 21st International Symposium on Human Identification was held October 11-14, 2010 in San Antonio, TX.  It is the major international forensic science meeting and was attended by more than 700 forensic scientists from around the world. For more information, visit http://ishi.crowdvine.com/.

Source:

ZyGEM Corp. Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals e-cigarette users with limited smoking history show similar DNA alterations as smokers